| Symbol | KYTX |
|---|---|
| Name | KYVERNA THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 5980 HORTON STREET,SUITE 550, EMERYVILLE, California, United States |
| Telephone | +1 (510) 626-8331 |
| Fax | — |
| — | |
| Website | https://www.kyvernatx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001994702 |
| Description | Kyverna Therapeutics is a cell therapy company engineering a new class of therapies for autoimmune and inflammatory diseases. The Kyverna therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the origin of autoimmune and inflammatory diseases. Kyvernas pipeline includes next-generation chimeric antigen receptor T-cell (CAR T) therapies in both autologous and allogeneic formats with properties well suited for use in B cell-driven autoimmune diseases. Additional info from NASDAQ: |
(80% Positive) KYVERNA THERAPEUTICS, INC. (KYTX) Provides Update on Kyverna for its transition to a commercial-stage organization
Read more(30% Negative) KYVERNA THERAPEUTICS, INC. (KYTX) Reports Q2 2026 Financial Results
Read moreKyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results
Read moreDac Nadia 🟢 acquired 300.0K shares (1 derivative) of Kyverna Therapeutics, Inc. (KYTX) at $9.00 ($2.7M) Transaction Date: May 04, 2026 | Filing ID: 209120
Read moreNew Form 3 - Kyverna Therapeutics, Inc. <b>Filed:</b> 2026-05-06 <b>AccNo:</b> 0001193125-26-209119 <b>Size:</b> 13 KB
Read more(90% Positive) KYVERNA THERAPEUTICS, INC. (KYTX) Announces Enrollment Update for management Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment
Read moreKyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting
Read more(85% Positive) KYVERNA THERAPEUTICS, INC. (KYTX) Announces Enrollment Update for profile Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07403188 | A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101 | — | Refractory Lupus Nephritis | Recruiting | 2025-11-24 | 2041-01-01 | ClinicalTrials.gov |
| NCT06475495 | Comparison of B-cell Depletion by Rituximab and Anti-CD 19 CAR-T Therapy in Pat… | Phase1 | Rheumatoid Arthritis | Active_Not_Recruiting | 2024-12-04 | 2027-06-01 | ClinicalTrials.gov |
| NCT06588491 | KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Ther… | Phase2 | Stiff-Person Syndrome | Active_Not_Recruiting | 2024-09-25 | 2026-12-01 | ClinicalTrials.gov |
| NCT06384976 | KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Pr… | Phase2 | Multiple Sclerosis, Primary Progressive | Active_Not_Recruiting | 2024-09-20 | 2029-01-01 | ClinicalTrials.gov |
| NCT06193889 | KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patie… | Phase2 | Myasthenia Gravis | Recruiting | 2024-08-28 | 2028-09-01 | ClinicalTrials.gov |
| NCT06400303 | KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Ther… | Phase1 | Systemic Sclerosis | Active_Not_Recruiting | 2024-08-06 | 2027-03-01 | ClinicalTrials.gov |
| NCT06451159 | A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment R… | Phase1 | Progressive Multiple Sclerosis | Active_Not_Recruiting | 2024-06-20 | 2027-02-01 | ClinicalTrials.gov |
| NCT06138132 | A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subje… | Phase1 | Multiple Sclerosis | Recruiting | 2024-04-10 | 2027-06-01 | ClinicalTrials.gov |
| NCT05938725 | KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Ther… | Phase1 | Lupus Nephritis | Active_Not_Recruiting | 2023-04-28 | 2027-08-01 | ClinicalTrials.gov |
| NCT06342960 | KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Ther… | Phase1 | Lupus Nephritis | Active_Not_Recruiting | 2022-12-01 | 2029-01-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| KYV-101 | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard lymphodepletion regimen | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard of Care Treatment | Drug | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| KYV-101 | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard lymphodepletion regimen | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard of Care Treatment | Drug | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| KYV-101 | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard lymphodepletion regimen | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard of Care Treatment | Drug | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| KYV-101 | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard lymphodepletion regimen | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard of Care Treatment | Drug | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| KYV-101 | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard lymphodepletion regimen | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard of Care Treatment | Drug | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| KYV-101 | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard lymphodepletion regimen | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard of Care Treatment | Drug | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| KYV-101 | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard lymphodepletion regimen | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard of Care Treatment | Drug | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| KYV-101 | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard lymphodepletion regimen | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard of Care Treatment | Drug | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| KYV-101 | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard lymphodepletion regimen | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard of Care Treatment | Drug | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| KYV-101 | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard lymphodepletion regimen | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard of Care Treatment | Drug | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| KYV-101 | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard lymphodepletion regimen | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard of Care Treatment | Drug | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| KYV-101 | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard lymphodepletion regimen | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard of Care Treatment | Drug | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| KYV-101 | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard lymphodepletion regimen | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard of Care Treatment | Drug | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| KYV-101 | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard lymphodepletion regimen | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard of Care Treatment | Drug | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Anti-CD20 mAB | Other | Phase PHASE2 | Multiple Sclerosis, Primary Progressive | ACTIVE_NOT_RECRUITING | NCT06384976 |
| Standard lymphodepletion regimen | Other | Phase PHASE2 | Multiple Sclerosis, Primary Progressive | ACTIVE_NOT_RECRUITING | NCT06384976 |
| KYV-101 | Other | Phase PHASE2 | Multiple Sclerosis, Primary Progressive | ACTIVE_NOT_RECRUITING | NCT06384976 |
| Standard lymphodepletion regimen | Other | Phase PHASE2 | Stiff-Person Syndrome | ACTIVE_NOT_RECRUITING | NCT06588491 |
| KYV-101 | Other | Preclinical | Refractory Lupus Nephritis | RECRUITING | NCT07403188 |
| Standard lymphodepletion regimen | Other | Phase PHASE1 | Systemic Sclerosis | ACTIVE_NOT_RECRUITING | NCT06400303 |
| KYV-101 | Other | Phase PHASE1 | Systemic Sclerosis | ACTIVE_NOT_RECRUITING | NCT06400303 |
| Standard lymphodepletion regimen | Other | Phase PHASE1 | Lupus Nephritis | ACTIVE_NOT_RECRUITING | NCT06342960 |
| KYV-101 anti-CD19 CAR-T cell therapy | Drug | Phase PHASE1 | Lupus Nephritis | ACTIVE_NOT_RECRUITING | NCT06342960 |
| Standard lymphodepletion regimen | Other | Phase PHASE1 | Lupus Nephritis | ACTIVE_NOT_RECRUITING | NCT05938725 |
| KYV-101 anti-CD19 CAR-T cell therapy | Drug | Phase PHASE1 | Lupus Nephritis | ACTIVE_NOT_RECRUITING | NCT05938725 |
| Chemotherapy: fludarabine (FLU) | Drug | Phase PHASE1 | Progressive Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT06451159 |
| Chemotherapy: cyclophosphamide (CYC) | Drug | Phase PHASE1 | Progressive Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT06451159 |
| KYV-101 (Biological) - 1 ×10^8 cells | Other | Phase PHASE1 | Progressive Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT06451159 |
| KYV-101 (Biological) - 0.33 ×10^8 cells | Other | Phase PHASE1 | Progressive Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT06451159 |
| Standard lymphodepletion regimen | Other | Phase PHASE1 | Multiple Sclerosis | RECRUITING | NCT06138132 |
| KYV-101 anti-CD19 CAR-T cell therapy | Drug | Phase PHASE1 | Multiple Sclerosis | RECRUITING | NCT06138132 |
| Rituximab (active comparator) | Other | Phase PHASE1 | Rheumatoid Arthritis | ACTIVE_NOT_RECRUITING | NCT06475495 |
| KYV101 | Other | Phase PHASE1 | Rheumatoid Arthritis | ACTIVE_NOT_RECRUITING | NCT06475495 |
| KYV-101 | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard lymphodepletion regimen | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard of Care Treatment | Drug | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |